Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled, dose-finding, Phase 2 study of its investigational single-dose sublingual sufentanil NanoTab for acute pain, ARX-04, successfully met its primary endpoint.  Results demonstrated that patients receiving 30 mcg sufentanil NanoTab doses, administered by a healthcare professional, no more frequently than once per hour, had significantly greater pain reduction as measured by Summed Pain Intensity Difference to baseline during the 12-hour study period (SPID-12) than placebo-treated patients (p=0.003).  Adverse events reported in the study were generally mild-to-moderate in nature, with two serious adverse events of post-surgical infection reported, both of which were determined by the investigator to be unrelated to study drug.  Two patients dropped out of the study due to adverse events, one patient's discontinuation considered unrelated to study drug, and the other considered probably related to study drug, both in the 30 mcg-treated group.

"The goal of this program, to find an effective sublingual sufentanil dose that could be administered less frequently by a healthcare professional than our patient-administered ARX-01 product candidate, has been met", said Dr. Pamela Palmer , Chief Medical Officer, AcelRx Pharmaceuticals.  "There is a need for a non-invasive, rapid-onset strong analgesic to provide short-term treatment of pain for the wounded soldier on the battlefield, the trauma victim at the site of a road-traffic accident, the migraine patient in the emergency room, or in g
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... , February 27, 2015 ... new study showing you trends, R&D progress, and predicted ... heading? What are the commercial prospects for this ... you potential revenues and other trends to 2025, discussing ... report lets you assess regenerative medicine : cell-based ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Vancouver, BC (PRWEB) February 28, 2015 Vancouver ... several personal injury claims are affected by time limits. They ... can weaken a person’s claim or even nullify it. Many ... adverse effects on a client’s rights under BC law. As ... who are affected by accidents should consult a personal injury ...
(Date:2/28/2015)... February 28, 2015 For those people ... person, the Mesothelioma Applied Research Foundation (Meso ... Tuesday, March 3, starting at 9:30 AM. , The ... registration. The broadcast can be accessed through any browser ... . , The Symposium is a unique event that ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
(Date:2/28/2015)... February 28, 2015 A case management ... lawsuits that have been filed by law firms including ... week in March, the Firm notes. , According ... involved in the federal litigation will meet on March ... to prescription therapy treatments designed to raise levels of ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... and anxiety are the heaviest smokers in the country, but ... assume that if their patients try to quit smoking, their ... a myth, according to Brian Hitsman, a tobacco addiction specialist ... School of Medicine. He also is a member of the ...
... Growing evidence shows that exposure to lead in the ... of hypertension. However, those studies have looked at lead ... of cumulative lead exposure over time. In a new ... (HSPH) and the University of Michigan School of Public ...
... a new report, University of Illinois professor Barbara H. Fiese urges ... family mealtimes as a matter of public policy. "There are ... their families as taking 18 to 20 minutes to eat together ... said Fiese, a U of I professor of human development and ...
... , , , ... of the nation,s leading experts in asthma, has been ... Erzurum will collaborate with experts in nuclear medicine and ... observe changes in the lungs of patients during an ...
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , BOSTON, Sept. 9 A ... a result of laboratory use and confinement. Developmental Context ... published in the September issue, Vol. 45 (5), of the ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) ...
Cached Medicine News:Health News:Doctors fear asking mentally ill to quit smoking 2Health News:Doctors fear asking mentally ill to quit smoking 3Health News:Lead in bone associated with increased risk of death from cardiovascular disease in men 2Health News:U of I acientist: Public policy should promote family mealtimes 2Health News:U of I acientist: Public policy should promote family mealtimes 3Health News:$750,000 Awarded for Cutting-Edge Asthma Research to 'See' Changes in the Lungs During an Attack 2Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
This 500 tip allows you to draw the full volume of compatible Biohit and Eppendorf pipettors....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples, and genomic DNA....
Medicine Products: